Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

Reinhard DummerUniversity Hospital Zürich, SwitzerlandCorrespondence[email protected]

Marc BeyerCharitè-Universitätsmedizin, Berlin, GermanyCorrespondence[email protected]

Kenneth HymesNew York University Clinical Cancer Center, NY, USA

Mirjam T. EppingThe Netherlands Cancer Institute, Amsterdam, The Netherlands

Rene BernardsThe Netherlands Cancer Institute, Amsterdam, The Netherlands

Matthias SteinhoffCharitè-Universitätsmedizin, Berlin, Germany

Wolfram SterryCharitè-Universitätsmedizin, Berlin, Germany

Helmut KerlMedical University of Graz, Austria

Karl HeathColumbia University, New York, NY, USA

Janet D. AhernColumbia University, New York, NY, USA

James S. HardwickColumbia University, New York, NY, USA

Jose Garcia-VargasColumbia University, New York, NY, USA

Katrin BaumannUniversity Hospital Zürich, Switzerland

Syed RizviColumbia University, New York, NY, USA

Stanley R. FrankelColumbia University, New York, NY, USA

Sean J. WhittakerKing's College London, UK

Chalid AssafCharitè-Universitätsmedizin, Berlin, Germany;Helios Klinikum, Krefeld, Germany

Your download is now in progress and you may close this window